Quanterix and STRATEC announce strategic partnership

17-Aug-2011 - USA

Quanterix Corporation, a company enabling a new generation of molecular diagnostic tests based on its revolutionary Single Molecule Array (SiMoA(TM)) technology, and STRATEC Biomedical AG, a worldwide leader in the development and manufacture of automated analyzer systems, announced an agreement to co-develop and manufacture a fully-automated instrument for Quanterix's SiMoA technology for use in both the life sciences and in vitro diagnostics (IVD) markets. Quanterix expects to launch a life sciences instrument in 2013, followed by the commercialization of an IVD platform in 2014.

As part of the agreement, Quanterix will receive access to STRATEC's platform technology, which will be customized to both optimize and automate the advanced applications of Quanterix's SiMoA technology. STRATEC will receive payments, as well as a minority stake of approximately 7% in the share capital of Quanterix, upon the achievement of technological milestones. After completion of the development phase, STRATEC will manufacture and supply the system and Quanterix has committed to order an agreed minimum volume of systems.

Other news from the department business & finance

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?

See the theme worlds for related content